Login | Register

Advanced Prostate Cancer Drug Xofigo Approved By FDA

Xofigo (radium Ra 223 dichloride) has been approved by the US FDA for symptomatic late-stage (metastatic) castration-resistant prostate cancer that has reached bones but not other organs, i.e. with no known visceral metastatic disease. The Food and Drug Administration (FDA) approved Xifogo under the priority review program, three months ahead of schedule...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *